It has also been proposed that cardiovascular medication, in particular, inhibitors of the Renin-Angiotensin-Aldosterone system (RAASi) elevate serum ACE2 activity, potentially contributes to the mortality of COVID-19 [4, 6, 7]. The gene discussed is REN; the disease is COVID-19.